In Q4, 2017, ISR asked a follow-up question to respondents who agreed that their company’s focus on developing new innovative treatments will impact its outsourcing practices in order to understand how outsourcing might change. The most likely change, reported by 41% of respondents, is that the organization will outsource more manufacturing of established products.

Originally published at Pharmaceutical Online.

View File